Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the C ...

Core Viewpoint - MannKind Corporation has initiated the INHALE-1 clinical study to evaluate the safety and efficacy of Afrezza inhaled insulin in youth aged 10 to under 18 years recently diagnosed with type 1 diabetes, aiming to reduce the burden of insulin injections for pediatric patients and their families [1][2]. Group 1: Study Details - The INHALE-1 study will assess Afrezza used in combination with subcutaneously injected basal insulin once daily, focusing on clinical outcomes and participant satisfaction [2]. - The study will enroll approximately 100 patients across about 10 clinical sites in the United States, with the first patient enrolled at the Barbara Davis Center for Diabetes in Aurora, Colorado [3]. - Participants will be followed for 13 weeks during the main phase, with an optional extension phase for up to 26 weeks [4]. Group 2: Primary Endpoint and Objectives - The primary endpoint is the percentage of participants with a Continuous Glucose Meter (CGM) measuring time in range (TIR) of 70-180 mg/dL at least 70% during the 14 days prior to the 13-week visit [4]. - The study aims to evaluate whether replacing most insulin injections with inhalations can ease the adjustment to managing type 1 diabetes for children and their families [2]. Group 3: Regulatory Status - The FDA is currently reviewing a supplemental Biologics License Application (sBLA) for Afrezza in children and adolescents with type 1 or type 2 diabetes, with a target action date of May 29, 2026 [5]. - If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over a century [5]. Group 4: Company Overview - MannKind Corporation is focused on transforming chronic disease care through innovative solutions, particularly in cardiometabolic and orphan lung diseases [9][10]. - The company aims to develop treatments that address serious unmet medical needs, including diabetes and related conditions [9].

Group 1 - Rainbow Rare Earths Ltd's Johannesburg pilot plant is producing commercial-grade rare earth products, which de-risks the project and supports plans for further downstream activities [1] - Cloudbreak Discovery PLC has acquired 90% of the Paterson gold-copper project in Western Australia and plans to use modern geophysics to refine drill targets near Greatland Gold's Telfer mine [1] - Valereum PLC has signed a Memorandum of Understanding with RWA.io and Defactor to explore compliant tokenized asset issuance and distribution, potentially increasing visibility for issuers and expanding access across regulated and decentralized markets [1] Group 2 - Arecor Therapeutics PLC is in discussions for a broader partnership regarding its Phase II ultra-concentrated insulin trial and is advancing its oral GLP-1 platform aimed at improving absorption and long-term growth [1] - Wellnex Life Ltd is reviewing takeover interest in its Pain Away brand and other assets while considering funding options as part of its turnaround plan [1]

Core Viewpoint - Avacta Therapeutics has appointed Francis Wilson as Chief Scientific Officer, recognizing his significant contributions to the development of the pre|CISION oncology delivery platform and his leadership in medicinal chemistry [1][5]. Company Leadership - Francis Wilson joined Avacta in September 2022 as Vice President of Chemistry and has been pivotal in advancing the pre|CISION platform, particularly the FAP-Exd (AVA6103) program, which is expected to enter clinical testing soon [2][4]. - Former CSO Michelle Morrow will be leaving the company to pursue other opportunities, and the company expresses gratitude for her contributions [4]. Expertise and Background - Francis Wilson has extensive experience in medicinal chemistry, having held various positions at Roche, Xenova, Cellzome, and Summit Therapeutics, where he led multiple programs from discovery to clinical development [3]. - He holds a chemistry degree and a Doctor of Philosophy from Oxford University, and is a Chartered Chemist and Fellow of the Royal Society of Chemistry [4]. Strategic Direction - CEO Christina Coughlin emphasized Wilson's deep knowledge of the pre|CISION platform and his ability to foster innovation, which will be crucial as the company enters a significant phase of preclinical development and intellectual property generation [5]. - Wilson expressed enthusiasm for his new role and the opportunity to advance the AVA6103 program, highlighting the importance of developing novel intellectual property around the pre|CISION platform [6]. Technology Overview - The pre|CISION platform is a proprietary tumor-activated delivery system designed to concentrate potent cancer therapies in the tumor microenvironment while minimizing exposure to healthy tissues [9][11]. - It utilizes a tumor-specific protease (fibroblast activation protein or FAP) to release active payloads in the tumor, optimizing dosing and reducing systemic toxicity [11].

Core Viewpoint - Sanofi's rilzabrutinib has received breakthrough therapy designation from the FDA and orphan drug designation in Japan for treating warm autoimmune hemolytic anemia (wAIHA), highlighting the urgent need for effective treatments for this rare autoimmune disorder [1][3][4]. Group 1: Designations and Studies - The FDA's breakthrough therapy designation aims to expedite the development of medicines for serious conditions, indicating rilzabrutinib may show substantial improvement over existing treatments [3]. - Rilzabrutinib is currently being evaluated in the LUMINA 2 phase 2b study and the new LUMINA 3 phase 3 study, which compares rilzabrutinib with placebo for wAIHA patients [2]. - There are no approved treatments specifically targeting the underlying causes of wAIHA, which can lead to severe health complications [2]. Group 2: Rilzabrutinib Overview - Rilzabrutinib is a novel oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, and under review in Japan [4][8]. - The drug addresses immune system dysregulation through multi-immune modulation, making it a potential treatment for various rare diseases [7][8]. - Rilzabrutinib has received multiple regulatory designations, including orphan drug status for autoimmune hemolytic anemia and other rare diseases [5][9]. Group 3: About wAIHA - Warm autoimmune hemolytic anemia is a rare and potentially life-threatening condition, affecting 4 to 24 individuals per 100,000 in the US and EU, and 3 to 10 per million in Japan [6]. - Symptoms include fatigue, dizziness, and serious complications like thromboembolism, emphasizing the need for effective treatments [6]. Group 4: Company Overview - Sanofi is an R&D-driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [10].

Core Viewpoint - REGENXBIO Inc. is under investigation for potential violations of federal securities laws following the FDA's clinical holds on its RGX-111 and RGX-121 programs, which resulted in a significant decline in the company's share price by 30-35% after the announcement [1]. Regulatory Compliance - SEC disclosure rules mandate that public companies must provide material information for informed investment decisions, with Item 8.01 of Form 8-K allowing disclosure of material events not covered by other items [2]. - Rule 10b-5 under the Securities Exchange Act of 1934 prohibits material misstatements and omissions in securities transactions, covering both false statements and omissions of necessary facts [2]. Company Communication - During the Q3 2025 earnings call, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections with no observations, which may have created an asymmetric view of the company's regulatory status by not disclosing safety concerns being evaluated [3]. - The Q3 2025 earnings call transcript notably lacked any discussion regarding the RGX-111 program for MPS I, despite it being a significant pipeline asset that later faced the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [4].

Core Viewpoint - InnoCare Pharma has received approval from the China National Medical Products Administration for the Investigational New Drug application to conduct clinical trials of ICP-538, marking it as the first VAV1 degrader approved for clinical trials in China and the second globally [1][2]. Group 1: Product Overview - ICP-538 is a novel, potent, and highly selective orally administered molecular glue degrader targeting VAV1, aimed at treating autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis [2][3]. - The drug induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner, facilitating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein [2]. Group 2: Mechanism of Action - Degradation of VAV1 effectively inhibits T-cell proliferation, differentiation, activation, and cytokine release, as well as B-cell activation and cytokine release, leading to anti-inflammatory and immunomodulatory effects [3]. - Preclinical studies indicate that ICP-538 results in significant reductions in cytokines associated with immune-mediated diseases, with no detectable effects on other proteins [3]. Group 3: Company Insights - InnoCare is a commercial stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and/or best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [4]. - The company has branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [4].

Core Viewpoint - Eisai Co., Ltd. and Biogen Inc. announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI has been designated for Priority Review by the National Medical Products Administration of China, which could significantly enhance patient access to treatment [1][2]. Group 1: Product Development and Approval - The subcutaneous formulation (SC-AI) of LEQEMBI allows for a once-weekly home administration, contrasting with the current intravenous method that requires hospital visits every two weeks [3]. - The injection time for each autoinjector is approximately 15 seconds, which could streamline the treatment process and reduce healthcare resource utilization [3]. - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China in 2024, a number expected to rise with the aging population [4]. Group 2: Market Access and Insurance - LEQEMBI was launched in China in June 2024 and has been included in the "Commercial Insurance Innovative Drug List," effective January 2026, which supports access to innovative medicines [5]. - Commercial insurance companies are expected to develop insurance products covering LEQEMBI based on this new list [5]. Group 3: Collaboration and Regulatory Strategy - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [6][11]. - The U.S. FDA approved the Biologics License Application for subcutaneous maintenance dosing of LEQEMBI in August 2025, with a supplemental application for initiation treatment accepted in January 2026 [8]. Group 4: Scientific Background - Lecanemab is a humanized monoclonal antibody targeting aggregated forms of amyloid-beta, which is believed to play a significant role in cognitive decline associated with Alzheimer's disease [8][10]. - The reduction of protofibrils may prevent the progression of Alzheimer's disease by mitigating neuronal damage and cognitive dysfunction [10]. Group 5: Company Overview - Eisai's corporate concept focuses on patient-centric healthcare, aiming to address unmet medical needs, particularly in neurology and oncology [13]. - Biogen, founded in 1978, is a leading biotechnology company that emphasizes innovative science to transform patient lives and create shareholder value [16].

Core Viewpoint - AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, experienced an 8.4% decline in its trading debut, closing at $14.65 after raising $200 million in its IPO, which was priced at $16 per share [1][2]. Group 1: Company Overview - AgomAb is based in Antwerp, Belgium, and focuses on immunology and inflammatory diseases, specifically developing an oral drug for Fibrostenosing Crohn's Disease and an inhalation treatment for a rare lung disease [3]. - The company has a market value of approximately $714 million based on outstanding shares [2]. Group 2: Financials and Funding - AgomAb raised nearly €300 million ($354 million) in private funding from notable investors, including Sanofi and Pfizer, prior to its IPO [4]. - The company reported a net loss of €45.1 million for the nine months ending September 30, compared to a net loss of €34.5 million for the same period the previous year [5]. Group 3: IPO Details - The IPO involved the sale of 12.5 million American depositary receipts (ADRs), which were marketed at $15 to $17 each [1]. - The offering was led by major financial institutions including JPMorgan Chase & Co. and Morgan Stanley, with the company's ADRs trading on the Nasdaq Global Market under the symbol AGMB [6].